Biodesix, Inc. and Inivata recently announced a partnership to advance and commercialize Next Generation Sequencing (NGS) tests (blood tests) that might have clinical applications for lung cancer. This agreement will help further develop the TAm-Seq™ technology platform, Inivata’s technology, and Biodesix’ development and commercialization ability in the United States market to provide these new and clinically usable tests to physicians.
“Approximately 30 percent of NSCLC patients are unable to obtain a biopsy or have insufficient tissue from a lung cancer biopsy to provide the diagnostic information needed for their care. Blood-based diagnostics can make a real difference in such cases,” said Michael Stocum, Inivata CEO. “Using Inivata’s circulating tumor DNA (ctDNA) analysis platform, we can now provide information that was previously unattainable for these patients, leading to better outcomes.”
Inivata and Biodesix agreed to use the NGS technology platform and assure research projects in non-small cell lung cancer (NSCLC). Biodesix and Inivata will both be funding studies to support and establish the NGS platform’s clinical utility and design observational assessments for later this year.
“Along with VeriStrat®, a serum protein test that is already commercially available to help physicians guide treatment decisions for patients with advanced NSCLC, the blood-based NGS tests we’re developing with Inivata will further drive towards precision medicine by guiding diagnosis, prognosis and monitoring for patients with NSCLC,” explained David Brunel CEO of Biodesix.
Nitzan Rosenfeld, Inivata CSO, said: “The combination of our world-class blood-based sequencing technology with Biodesix’ ability to develop and establish diagnostics as standard of care creates a strong platform to develop new highly clinically relevant tests. We are excited to be working with Biodesix to improve the care offered to cancer patients.”
Lung cancer is the number one cause of cancer death worldwide. Inivata and Biodesix plan to work together along with top pharmaceutical companies and opinion leaders to continue to offer improved diagnostics to detect the disease earlier, improving patient outcomes.
Earlier this month, Threshold Pharmaceuticals, a development-stage biopharmaceutical company announced the initiation of an international 440-patient, double-blind, randomized and placebo controlled trial using TH-302 for the treatment of advanced non-squamous non-small cell lung carcinoma (NSCLC). Lung cancer is the second most common cancer in both men and women, accounting for about 13% of all new cancers and 27% of all cancer deaths. Approximately 85% of all lung cancers are diagnosed as NSCLCs, 70-75% of which are histologically classified as non-squamous.